SCHEMBL1781795

SCHEMBL1781795

Cn1c(=O)[nH]nc(N2CCN(c3cccc(F)c3)CC2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.47
▸ HTR6 P50406 1/20 0.44
▸ HTR7 P34969 1/20 0.42
▸ SLC2A1 P11166 1/20 0.41
▸ SLC2A2 P11168 1/20 0.41
▸ SLC2A3 P11169 1/20 0.41
▸ PIK3CD O00329 1/20 0.41
▸ PIK3R1 P27986 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADAMTS5 Q9UNA0 2/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ C1S P09871 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ SCD O00767 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781669 0.86 KCNH2 (0.52) HTR6HTR7HTR1AHTR2AHTT
SCHEMBL1782667 0.84 CYP1A2 (0.54) HTR7HTR1ADRD2HTR2AHTT
SCHEMBL10373948 0.73 BPTF (0.54) HTR7SLC2A1SLC2A2SLC2A3HTR1A
SCHEMBL20699709 0.73 BPTF (0.54) HTR7SLC2A1SLC2A2SLC2A3HTR1A
SCHEMBL1783749 0.72 GPR183 (0.46) DRD2PARP1
SCHEMBL7927182 0.72 ADRA2C (0.65) HTR6C1SHTTSMN1; SMN2
SCHEMBL1780313 0.71 HTT (0.51) HTR2APARP1SCDHTT
SCHEMBL1782559 0.71 HTT (0.53) SCDHTT
SCHEMBL28481556 0.69 DRD2 (0.68) HTR7DRD2SMN1; SMN2
SCHEMBL18741370 0.68 CHRNA7 (0.62) HTR7DRD2HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328886-B1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PF MEDICAMENT (FR) 2016-12-28 — — EP disclosed
US-8618287-B2 Derivatives of triazines and uracils, their preparation and their application in human therapeutics PIERRE FABRE MEDICAMENT (FR) 2013-12-31 — — US disclosed
EP-2328886-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS Pierre Fabre Médicament (FR) 2011-06-08 — — EP disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
WO-2010006962-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2010-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS UNG, TYMS, UMPS MAOB 300/4885HTR6 1616/4885HTR7 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback